Solara Active Pharma Sciences Releases Audited Financial Results for FY 2025-26
Solara Active Pharma Sciences Limited announced its audited and unaudited consolidated and standalone financial results for the year and quarter ended March 31, 2026. The company confirmed that its Board of Directors had considered and approved the results during a meeting held on May 15, 2026.Statutory auditors, Deloitte Haskins & Sells LLP, issued an unmodified opinion on the Consolidated Financial Results for the year ended March 31, 2026. The auditors also issued an unmodified conclusion regarding the limited review of the consolidated results for the quarter ended March 31, 2026.
Financial Performance Highlights
The financial results provide a comparison of the current fiscal year against the previous year.Consolidated Financial Results Summary (Rs. in Crores)
The combined financial results show the following figures for the year ended March 31, 2026, compared to the previous year:| Particulars | Year Ended 31.03.2026 (AUDITED) | Year Ended 31.03.2025 (AUDITED) |
|---|---|---|
| Revenue from operations | 1,368.98 | 1,283.76 |
| Total income (I + II) | 1,375.14 | 1,292.08 |
| Total expenses | 1,376.66 | 1,291.54 |
| Profit/(loss) before tax | (7.41) | 0.54 |
| Total comprehensive income/(loss) | (4.56) | 1.52 |
Standalone Financial Results Summary (Rs. in Crores)
For the Standalone segment, the key financial metrics for the year ended March 31, 2026, are reported as follows:| Particulars | Year Ended 31.03.2026 (AUDITED) | Year Ended 31.03.2025 (AUDITED) |
|---|---|---|
| Revenue from operations | 1,368.98 | 1,283.76 |
| Total income (I + II) | 1,374.87 | 1,292.90 |
| Total expenses | 1,376.22 | 1,293.98 |
| Profit/(loss) before tax | (7.24) | (1.08) |
| Total comprehensive income/(loss) | (3.97) | (0.02) |
Balance Sheet Snapshot
The consolidated balance sheets illustrate the company's assets and liabilities as of the end of the financial year.Consolidated Balance Sheet (Rs. In Crores)
| Particulars | As at March 31, 2026 (AUDITED) | As at March 31, 2025 (AUDITED) |
|---|---|---|
| Total Assets | 2,332.59 | 2,231.84 |
| Non-current assets | 1,474.49 | 1,503.11 |
| Current assets | 858.10 | 728.73 |
| Total Equity and Liabilities | 2,332.59 | 2,231.84 |
| Total Equity | 1,255.55 | 1,096.91 |
| Total Liabilities | 1,077.04 | 1,134.93 |
Cash Flow Generation
The cash flow statements provide a detailed look at operational cash generation for both consolidated and standalone entities.Consolidated Statement of Cash Flows (Rs. In Crores)
| Particulars | Year Ended March 31, 2026 | Year Ended March 31, 2025 |
|---|---|---|
| Net cash flow generated from operating activities (A) | 152.91 | 212.82 |
| Net cash flow utilised in investing activities (B) | (98.83) | (36.83) |
| Net cash flow utilised in financing activities (C) | (53.55) | (180.48) |
| Net increase in cash and cash equivalents (A+B+C) | 0.53 | (4.49) |
| Cash and cash equivalents at the end of the year | 4.48 | 3.95 |
Standalone Statement of Cash Flows (Rs. In Crores)
| Particulars | Year Ended March 31, 2026 | Year Ended March 31, 2025 |
|---|---|---|
| Net cash flow generated from operating activities (A) | 152.89 | 212.80 |
| Net cash flow utilised in investing activities (B) | (50.14) | (36.83) |
| Net cash flow utilised in financing activities (C) | (102.56) | (180.48) |
| Net increase in cash and cash equivalents (A+B+C) | 0.19 | (4.51) |
Corporate Update
The Board of Directors noted that the Company continues to expect renewal of its working capital facilities and anticipates increasing revenues and margins on its products, thereby expecting cash inflows from operations adequate to meet future obligations.The company remains focused on its operations in the Active Pharmaceutical Ingredient (API) segment. Additionally, the Parent Company had previously incorporated a wholly owned subsidiary, Synthix Global Pharma Solutions Limited, on April 29, 2025, as part of plans to explore the potential demerger of the CRAMS and Polymers business into an independent listed entity.
SOLARA Stock Price Movement
Shares of Solara Active Pharma Sciences Limited are edging higher to ₹580.6 as of 2:49 PM today, rallying 14.36% on strong momentum. The stock has seen significant trading interest, with 2.92 million shares transacted throughout the live day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.